Core Insights - Tempus AI is focusing on expanding partnerships with existing customers to drive growth, highlighted by a recent collaboration with AstraZeneca and Pathos Inc. to create a multimodal oncology foundation model [1][2][9] - The total remaining contract value for Tempus AI has exceeded $1 billion as of April 2025, indicating strong demand for its services [2][9] - Tempus AI is also enhancing its partnership with Illumina to integrate molecular profiling into standard care across various disease areas, which is expected to improve precision medicine accessibility [3][4][9] Partnership Developments - The collaboration with AstraZeneca involves a three-year, $200 million agreement aimed at leveraging over 300 petabytes of healthcare data to enhance clinical success rates in drug development [1][2] - Tempus AI's partnership with Illumina aims to address gaps in molecular profiling, enhancing AI-driven molecular analysis technologies to support comprehensive genomic profiling beyond cancer [3][4] - The company has also strengthened its relationship with Personalis to offer their minimal residual disease product, expanding market access for both companies [5] Financial Performance - Tempus AI shares have increased by 77% over the past year, outperforming the industry growth of 39.7% [6] - The company's valuation is stretched, with a forward five-year Price-to-Sales ratio of 8.85X compared to the industry average of 6.34X, indicating potential overvaluation concerns [7] Earnings Estimates - Current earnings estimates for Tempus AI show a projected loss of $0.21 for the current quarter and $0.62 for the current year, with slight improvements expected in the following year [11]